LAS VEGAS, Sept. 3, 2019 /PRNewswire/ — GB Sciences, Inc. (OTCQB: GBLX) today announced that it has received notification from the U.S. Drug Enforcement Agency (DEA) that prior to making any decisions on the pending applications, the DEA intends to distribute regulations that govern the program of growing marijuana for scientific research under DEA registration. GB Sciences is one of just 33 companies that applied to the DEA to become registered under the Controlled Substances Act (CSA) to grow (manufacture) marijuana in order to supply DEA-registered researchers in the United States. Last week, after a three-year delay and following pressure by Congress, patients and researchers, the DEA announced that it will move forward with creating revised regulations and with reviewing the applications.
“We are well-positioned to meet and exceed the DEA’s criteria, and we intend to aggressively pursue federal licensure,” said Dr. Andrea Small-Howard, Chief Science Officer and Director of GB Sciences. “The sophistication of our facilities, our team’s deep scientific experience, and our groundbreaking cannabinoid therapies are unparalleled in the United States.”
According to the letter from the DEA, it is looking to facilitate research, advance scientific understanding about the effects of marijuana, and potentially aid in the development of safe and effective drug products that may be approved for marketing by the Food and Drug Administration.
GB Sciences’ 28,000-square-foot facility in Las Vegas, Nevada features one of the only pharmaceutical-grade “cleanroom-type” grows in the United States. The company’s groundbreaking research program, led by Dr. Small-Howard with nine university research partners in the U.S. and internationally, has created a patent portfolio of cannabis-based therapies that cover over 60 disease and health conditions including Parkinson’s disease, neuropathic pain, and cardiac hypertrophy.
About GB Sciences
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
Liz Bianco, Director of Publicity, [email protected]
SOURCE GB Sciences, Inc.
This information is being sent to you by:
PR Newswire, A Cision Company
200 Vesey St., 19th Floor, New York, NY, 10281